(Total Views: 635)
Posted On: 01/13/2021 6:07:29 PM
Post# of 155843
Another failed ph3 s/c study. We can appreciate even more what cd12 has accomplished.
Alexion Pharma pauses further enrollment in COVID-19 drug study
Published: Jan. 13, 2021 at 5:13 p.m. ET
Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data monitoring board. The independent data monitoring committee for the Phase 3 study of the drug Ultomiris said further enrollment of patients should be paused pending more data analysis as the treatment was not looking to be effective in treating COVID-19 patients on ventilators when compared with standard care, the company said.
Alexion Pharma pauses further enrollment in COVID-19 drug study
Published: Jan. 13, 2021 at 5:13 p.m. ET
Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data monitoring board. The independent data monitoring committee for the Phase 3 study of the drug Ultomiris said further enrollment of patients should be paused pending more data analysis as the treatment was not looking to be effective in treating COVID-19 patients on ventilators when compared with standard care, the company said.
(6)
(0)
